LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors

被引：3
|
作者：
Luscher, Thomas F. [1 ]
机构：
[1] Zurich Heart House, Careum Campus,Moussonstr 4, CH-8091 Zurich, Switzerland
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷 / 17期
关键词：
FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR RISK; LIFETIME RISK; ATHEROSCLEROSIS; DISEASE; ADULTS;
D O I：
10.1093/eurheartj/ehw150
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1337 / 1340
页数：4
相关论文
共 50 条
  • [1] PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
    Wang, Yan
    Liu, Zhao-Peng
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2019, 19 (02) : 165 - 176
  • [2] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    [J]. ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [3] PCSK9 MUTATIONS AND LDL-CHOLESTEROL IN THE BOGALUSA HEART STUDY
    Hallman, D. M.
    Srinivasan, S.
    Chen, W.
    Boerwinkle, E.
    Berenson, G.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [4] Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol
    Thomas F. Whayne
    [J]. Drugs, 2018, 78 : 287 - 291
  • [5] Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol
    Whayne, Thomas F.
    [J]. DRUGS, 2018, 78 (03) : 287 - 291
  • [6] PCSK9—an exciting target for reducing LDL-cholesterol levels
    D. John Betteridge
    [J]. Nature Reviews Endocrinology, 2013, 9 : 76 - 78
  • [7] The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
    Piper, Derek E.
    Jackson, Simon
    Liu, Qiang
    Romanow, William G.
    Shetterly, Susan
    Thibault, Stephen T.
    Shan, Bei
    Walker, Nigel P. C.
    [J]. STRUCTURE, 2007, 15 (05) : 545 - 552
  • [8] LDL-CHOLESTEROL REDUCTION WITH PCSK9 INHIBITORS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
    Casula, Manuela
    Scotti, Lorenza
    Bernocchi, Ottavia
    Galimberti, Federica
    Tragni, Elena
    Corrao, Giovanni
    Catapano, Alberico Luigi
    [J]. ATHEROSCLEROSIS, 2017, 263 : E244 - E244
  • [9] Evolocumab (Repatha) A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1479): : 139 - 140
  • [10] PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
    Luquero, Aureli
    Badimon, Lina
    Borrell-Pages, Maria
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
12345